A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis (NCT05437263)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Brepocitinib in Adults With Dermatomyositis
🩺 Plain-English Summary (8th-Grade Level)
This is a phase 3, multicenter, randomized, placebo-controlled, double-blind study of treatment with brepocitinib (TYK2/JAK1 inhibitor) in adults with dermatomyositis (DM). The primary objective of this study is to assess the efficacy of two dose levels of brepocitinib in comparison to placebo, as measured by differences in the Total Improvement Score (TIS). After 52 weeks of double-blind treatment, participants have the option to continue therapy in a 52 week open-label extension phase where all participants will receive brepocitinib.
Who can join: Review the eligibility criteria below.
Location: Clinical Trial Site — Phoenix, Arizona
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (109 Sites)
Showing the first 25 of 109 sites.
- Clinical Trial Site — Phoenix, Arizona
- Clinical Trial Site — Scottsdale, Arizona
- Clinical Trial Site — Scottsdale, Arizona
- Clinical Trial Site — Irvine, California
- Clinical Trial Site — Los Angeles, California
- Clinical Trial Site — San Francisco, California
- Clinical Trial Site — Aurora, Colorado
- Clinical Trial Site — Denver, Colorado
- Clinical Trial Site — Boynton Beach, Florida
- Clinical Trial Site — Gainesville, Florida
- Clinical Trial Site — Jacksonville, Florida
- Clinical Trial Site — Plantation, Florida
- Clinical Trial Site — Tampa, Florida
- Clinical Trial Site — Atlanta, Georgia
- Clinical Trial Site — Augusta, Georgia
- Clinical Trial Site — Marietta, Georgia
- Clinical Trial Site — Chicago, Illinois
- Clinical Trial Site — Iowa City, Iowa
- Clinical Trial Site — Kansas City, Kansas
- Clinical Trial Site — New Orleans, Louisiana
- Clinical Trial Site — New Orleans, Louisiana
- Clinical Trial Site — Baltimore, Maryland
- Clinical Trial Site — Boston, Massachusetts
- Clinical Trial Site — Ann Arbor, Michigan
- Clinical Trial Site — Minneapolis, Minnesota
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Dermatomyositis
- A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis — Oceanside, California
- Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis — Palo Alto, California
- Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis — Cleveland, Ohio
- Adult and Juvenile Myositis — Atlanta, Georgia
- Clinical Responsiveness of Dermatomyositis Using Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) — Philadelphia, Pennsylvania
Explore by condition: All Dermatomyositis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.